Item 4 — Purpose of Transaction
The Reporting Persons originally acquired the securities reported herein because they believe the securities are undervalued and represent an attractive investment opportunity and they continue to hold the shares of Common Stock reported herein for investment purposes. The Reporting Persons previously reported their beneficial ownership on Schedule 13G pursuant to Rule 13d-1(c) under the Act. As a result of the acquisition of additional shares of Common Stock described in Items 3 and 5(c), the Reporting Persons' aggregate beneficial ownership has equaled or exceeded 20% of the outstanding Common Stock. Accordingly, the Reporting Persons are no longer eligible to report on Schedule 13G under Rule 13d-1(c)(3) and are filing this Schedule 13D pursuant to Rule 13d-1(f)(1). On June 24, 2026, the Issuer, Peregrine Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Issuer ("Merger Sub"), and Remix Therapeutics, Inc., a Delaware corporation ("Remix") entered into an Agreement and Plan of Merger (the "Merger Agreement") substantially in the form attached as Exhibit 99.2 to this Schedule 13D, pursuant to which Merger Sub will merge with and into Remix, with Remix surviving the merger and becoming a wholly owned subsidiary of the Issuer (the "Merger"). Following the Merger, the combined company is expected to be renamed "Remix Therapeutics, Inc." and to trade on Nasdaq under the symbol "RMTX." In connection with the Merger, the Lynx1 Fund has agreed to participate in a financing (the "Concurrent Financing") in which it will (i) purchase shares of Remix common stock pursuant to a subscription agreement (the "Subscription Agreement") substantially in the form attached as Exhibit 99.3 to this Schedule 13D and (ii) purchase convertible notes pursuant to a convertible promissory note purchase agreement. The consummation of the Concurrent Financing is conditioned on the satisfaction or waiver of certain conditions to the Merger. In addition, in connection with the Concurrent Financing, an affiliate of the Investment Manager will enter in to a registration rights agreement (the "Registration Rights Agreement") with the Issuer and Remix, substantially in the form attached as Exhibit 99.4 to this Schedule 13D, providing for the registration for resale of the shares of Common Stock issuable in respect of the securities purchased in the Concurrent Financing. In addition, the Issuer and a third party rights agent will enter into a Contingent Value Rights Agreement (the "CVR Agreement") substantially in the form attached as Exhibit 99.5 to this Schedule 13D, pursuant to which the Issuer's common stockholders of record will receive one contingent value right for each outstanding share of Common Stock held by such stockholder. As a result of the foregoing, the Reporting Persons expect to acquire additional shares of Common Stock at the effective time of the Merger in respect of the Remix securities they have agreed to purchase in the Concurrent Financing. The Reporting Persons do not presently beneficially own such shares of Common Stock, the issuance of which is contingent on the consummation of the Merger. In addition, as a holder of record of Common Stock, the Reporting Persons will be entitled to receive one contingent value right for each share of Common Stock held as of the close of business on the last business day prior to the Effective Time, pursuant to a Contingent Value Rights Agreement to be entered into by the Issuer as described in the Issuer's filings. The foregoing summaries of the Merger Agreement, the Subscription Agreement, the Registration Rights Agreement and the CVR Agreement are qualified in their entireties by reference to the full texts of such agreements, the forms of which are included as Exhibit 99.2, Exhibit 99.3, Exhibit 99.4 and Exhibit 99.5, respectively, hereto and are incorporated by reference herein. The Reporting Persons may engage in discussions with management, the board of directors (the "Board"), other stockholders of the Issuer, and other persons regarding the Issuer, including with respect to its business, operations, strategy, capital structure, and governance, and the Merger, though the Reporting Persons may change its intentions with respect to any and all of the foregoing. The Reporting Persons may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such transactions. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and depending upon various factors, including without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities